Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 29;12(12):1118. doi: 10.1038/s41419-021-04407-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — A siRNA-mediated EZH2 knockdown leads to a global loss of H3K27me3 and increased NFATc1 protein levels in pG-2 cells, as assessed by western blot. The densitometry values provided here represent H3K27me3/H3, NFATc1/Actin, and H3K27ac/H3 signals, respectively. B Schematic representation of the groups of CAF-treated tumors from Jannasch et al. [31] (left panel). Representative images of paraffin-embedded tumors from group 1 (control), group 2 (acute phase), and group 3 (regrowth phase) stained for EZH2 and NFATc1 (right panel). Scale bar = 50 µm. C Expression levels of EZH2 and NFATc1 alone (left charts) and anti-correlated with each other (right chart) in BC TMA samples (n = 119). D and E Distribution of EZH2 and NFATc1 expression levels in Metabolic gEne RApid Visualizer database (D; MERAV; http://merav.wi.mit.edu) and R2: Genomics Analysis and Visualization Platform (E; https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). A significant anti-correlation between EZH2 and NFATc1 expression was observed (D and E). F–H Survival analyses of BLBC patients (PAM50 classification) showing overall survival (OS) advantage for the EZH2^high (F) or EZH2^high/NFATC1^low (H) and a poorer survival for the NFATC1^high (G) and EZH2^low/NFATC1^high (H) -expressing groups (H: based on the z-score (EZH2)/z-score(NFATc1) ratio). Expression and survival data of BLBC patient data were extracted from the TCGA-BRCA dataset on the Xena browser (link: https://xenabrowser.net/). Statistical tests: Fisher exact test (C), Pearson correlation (D, E), Log-rank test (F–H). All experiments were performed in at least biological triplicates (n = 3).